CLASS II ONGOING Device recall · Reported 12 Feb 2025 · FDA Enforcement Report

NeiMed NasoGel for DRY Noses recalled by Neilmed Pharmaceuticals

Neilmed Pharmaceuticals is recalling NeiMed NasoGel for DRY Noses, distributed nationwide in the US. The recall was initiated on 28 Dec 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesNasoGel Spray UDI-DI/UPC code: 00705928045309 SKU / Lot Numbers: GSP30-2R-48-ENU-USL / NGS751 GSP30-0R-96-ENU-USL / NGS757 and NGS762 GSP30-ARA-INTL / NGS762 GSP30-SWE-INTL / NGS754 GSP30-ENG-INT / NGS755 GSP30-MAL-INTL / NGS756 GSP30-SPA-INT / NGS760 and NGS761
Quantity recalled89,312

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1105-2025
FDA event ID
96076
Recalling firm
Neilmed Pharmaceuticals, Santa Rosa, CA
Classification
Class II
Status
Ongoing
Recall initiated
28 Dec 2024
FDA classified
5 Feb 2025
Reported
12 Feb 2025
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

28 Dec 2024Recall initiated by company
5 Feb 2025Classified by FDA+39 days
12 Feb 2025Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Due to nasal spray stability failure for bioburden.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

NeiMed NasoGel for DRY NOSES UDI-DI/UPC code: 00705928045309 SKU GSP30-2R-48-ENU-USL GSP30-0R-96-ENU-USL GSP30-ARA-INTL GSP30-SWE-INTL GSP30-ENG-INT GSP30-MAL-INTL GSP30-SPA-INT NasoGel Spray is a saline-based gel formula that can be sprayed to moisturize and lubricate dry and irritated anterior or front of nasal passages caused by dry climate and indoor heat.

Where it was distributed

Worldwide - U.S. Nationwide distribution in the states of AL, AZ, CA, CO, CT, FL, GA, ID, IL, IN, KY, MA, MD, MI, MN, MO, NC, NJ, NM, NY, OH, OR, PA, RI, SC, TN, TX, VA, VT, WA, and WI. The countries of Bahrain, Ireland, Malaysia, Mexico, and United Kingdom.

Nationwide AlabamaArizonaCaliforniaColoradoConnecticutFloridaGeorgiaIdahoIllinoisIndianaKentuckyMassachusettsMarylandMichiganMinnesotaMissouriNorth CarolinaNew JerseyNew MexicoNew York

Questions about this recall

Why was it recalled?

Due to nasal spray stability failure for bioburden.

Which lots are affected?

NasoGel Spray UDI-DI/UPC code: 00705928045309 SKU / Lot Numbers: GSP30-2R-48-ENU-USL / NGS751 GSP30-0R-96-ENU-USL / NGS757 and NGS762 GSP30-ARA-INTL / NGS762 GSP30-SWE-INTL / NGS754 GSP30-ENG-INT / NGS755 GSP30-MAL-INTL / NGS756 GSP30-SPA-INT / NGS760 and NGS761

Where was it sold?

Worldwide - U.S. Nationwide distribution in the states of AL, AZ, CA, CO, CT, FL, GA, ID, IL, IN, KY, MA, MD, MI, MN, MO, NC, NJ, NM, NY, OH, OR, PA, RI, SC, TN, TX, VA, VT, WA, and WI. The countries of Bahrain, Ireland, Malaysia, Mexico, and United Kingdom.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Neilmed Pharmaceuticals

All 2
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIISinuFrin Decongestant (oxymetazoline HCl) Nasal Solution recalledSinufrin Quick Relief DecongestantNeilmed PharmaceuticalsOtherNationwide

Other Other Medical Devices recalls

All 13,908